CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
The combined organization will unite technologies and platforms to benefit customers with expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening, and point-of-care diagnostics offerings and will meet patient testing needs at reference labs, hospitals, physicians’ offices, urgent care centers, and at-home and retail locations.
Quidel’s president and chief executive officer, Douglas Bryant, will serve as chairman and chief executive officer of the combined company. The transaction, which is subject to approval by both companies’ shareholders as well as customary closing conditions and regulatory approvals, is expected to close in the first half of 2022.
Pages: 1 2